PubRank

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (CheckMate 143)

Clinical Trial ID NCT02017717

PubWeight™ 34.46‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02017717

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014 2.71
2 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
3 Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 2015 1.50
4 The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int 2015 1.50
5 Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer 2016 1.41
6 PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 2015 1.16
7 Immunotherapy advances for glioblastoma. Neuro Oncol 2014 1.07
8 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
9 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
10 Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro Oncol 2015 0.95
11 What next for newly diagnosed glioblastoma? Future Oncol 2015 0.94
12 Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res 2014 0.92
13 Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015 0.89
14 Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2015 0.88
15 Immunotherapy for cancer in the central nervous system: Current and future directions. Oncoimmunology 2015 0.88
16 PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 2016 0.85
17 Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) 2015 0.85
18 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
19 Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. J Clin Med Res 2015 0.85
20 The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro Oncol 2015 0.84
21 Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015 0.82
22 Advances in the treatment of newly diagnosed glioblastoma. BMC Med 2015 0.82
23 Immunotherapeutic advancements for glioblastoma. Front Oncol 2015 0.81
24 Antibody-based immunotherapy for malignant glioma. Semin Oncol 2014 0.80
25 Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme. Front Oncol 2014 0.79
26 Immunomonitoring in glioma immunotherapy: current status and future perspectives. J Neurooncol 2015 0.79
27 Immunomodulation: checkpoint blockade etc. Neuro Oncol 2015 0.78
28 Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res 2016 0.77
29 Emerging immunotherapies for glioblastoma. Expert Opin Emerg Drugs 2016 0.77
30 Concepts of immunotherapy for glioma. J Neurooncol 2015 0.77
31 Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther 2016 0.77
32 Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. Onco Targets Ther 2016 0.75
33 Genomic discoveries in adult astrocytoma. Curr Opin Genet Dev 2015 0.75
34 Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol 2016 0.75
35 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
36 Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opin Investig Drugs 2016 0.75
37 High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol 2016 0.75
Next 100